Advances in the diagnosis and management of von Willebrand disease

References

• Castaman G, Federici AB, Rodeghiero F, Mannucci PM. von Willebrand’s disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003;88:94–108.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987;69:454–459.
   PubMed Web of Science ®Google Scholar
• Federici AB, Castaman G, Mannucci PM. Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8:607–621.
   Google Scholar
• Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520–525.
   PubMed Web of Science ®Google Scholar
• Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004;10\(Suppl. 4):169–176.
   PubMed Web of Science ®Google Scholar
• Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand’s disease. I. Phenotypic variation within families. Blood 1979;54:117–136.
   Google Scholar
• Weiss HJ, Pietu G, Rabinowitz R, Girma JP, Rogers J, Meyer D. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma—platelet content of factor VIII/von Willebrand factor insubtypes of classic (type I) and variant (IIA) von Willebrand’s disease. J Lab Chin Med 1983;101:411–425.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985;66:796–802.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Lillicrap D, Lazzari MA, et al. von Willebrand disease: Laboratory aspects of diagnosis and treatment. Haemophilia 2004;10\(Suppl. 4):164–168.
   PubMed Web of Science ®Google Scholar
• Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004;10: 199–217.
   PubMed Web of Science ®Google Scholar
• Weiss HJ, Meyer D, Rabinowitz R, et al. Pseudo-von Willebrand’s disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982;306:326–333.
   Google Scholar
• Miller JL, Castella A. Platelet-type von Willebrand’s disease: Characterization of a new bleeding disorder. Blood 1982;60:790–794.
   PubMed Web of Science ®Google Scholar
• Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989;74:1591–1599.
   PubMed Web of Science ®Google Scholar
• Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990;75:20–26.
   Google Scholar
• Fressinaud E, Veyradier A, Trichaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998;91:1325–1331.
   PubMed Web of Science ®Google Scholar
• Franchini M. The platelet function analyzer (PFA-100): An update on its clinical use. Chin Lab 2005;51:367–372.
   Google Scholar
• Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease-single center comparison of four different assays. Thromb Haemost 2000;84:1127–1128.
   PubMed Web of Science ®Google Scholar
• Federici AB, de Groot PG, Moia M, Ijsseldijk MJ, Sixma JJ, Mannucci PM. Type I von Willebrand disease, subtype "platelet low": Decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. Br J Haematol 1993;83:88–93.
   PubMed Web of Science ®Google Scholar
• Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, Jorieux S, Mazurier C. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. INSERM network on molecular abnormalities in von Willebrand disease. Thromb Haemost 1997;78:451–456.
   PubMed Web of Science ®Google Scholar
• Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992;267: 4424–4430.
   PubMed Web of Science ®Google Scholar
• Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Best Pract Res Chin Haematol 2001;14:281–298.
   PubMed Web of Science ®Google Scholar
• Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005;56:173–1791.
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Type IIB von Willebrand disease: A paradox explains how von Willebrand factor works. J Thromb Haemost 2004;2:2–6.
   PubMed Web of Science ®Google Scholar
• Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84:289–297.
   PubMed Web of Science ®Google Scholar
• Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain Al with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 2000;275:7539–7546.
   Google Scholar
• Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M:Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor Al domain causes deficient binding of von Willebrand factor to platelets. Blood 1996;88: 2259–2568.
   PubMed Web of Science ®Google Scholar
• Hillery CA, Mancuso DJ, Sadler JE, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein lb binding domain selectively impair ristocetin-but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998;91:1572–1581.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Lombardi R, Castaman G, et al. von Willebrand disease "Vicenza" with larger-than-normal (supra-normal) von Willebrand factor multimers. Blood 1988;71: 65–70.
   PubMed Web of Science ®Google Scholar
• Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand disease type 2M "Vicenza" in Italian and German patients: Identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000;82:136–140.
   Google Scholar
• Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001;14:337–347.
   PubMed Web of Science ®Google Scholar
• Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–174.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand’s disease: Effects on replacement therapy. Blood 1981;57:25–31.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004;10: 218–231.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004;351:683–694.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245–253.
   PubMed Web of Science ®Google Scholar
• Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001;66:280–284.
   PubMed Web of Science ®Google Scholar
• Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004;103:2032–2038.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Federici AB. Management of inherited von Willebrand disease. Best Pract Res Chin Haematol 2001;14: 455–462.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991;5:155–161.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hypona-tremia and seizures in young children given DDAVP. Am J Hematol 1989;31:199–202.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989;2:675.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915–1919.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia 2000;6\(Suppl. 1):60–67.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM. and the Alphanate Study Group Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002;99:450–456.
   PubMed Web of Science ®Google Scholar
• Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G. Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand’s disease. Haematologica 2003;88:1279–1283.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR. High levels of factor VIII and venous thrombosis. Throm Haemost 2000;83:1–2.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002;88:378–379.
   PubMed Web of Science ®Google Scholar
• Makris M, Colvin B, Gupta V, Shields ML, Smith MR Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 2002;88:387–388.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005;42:29–35.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, Tedesco F. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987;39:467–470.
   PubMed Web of Science ®Google Scholar